ImmunoPrecise Antibodies Total Revenue

ImmunoPrecise Antibodies (IPA) currently reports a total revenue of $18M as of January 2026. That compares with $24M in the prior-year period — down 23.3% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore ImmunoPrecise Antibodies's total revenue history and peer comparisons.

ImmunoPrecise Antibodies's total revenue decreased from $24M to $18M — a 23.3% year-over-year decrease (period ending January 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ImmunoPrecise Antibodies's total revenue of $18M is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

ImmunoPrecise Antibodies reported $18M in total revenue as of January 2026. That compares with $24M in the prior-year period — down 23.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $18M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for ImmunoPrecise Antibodies, and consider following IPA for alerts when major investors trade the stock.